强生
JNJ176.910USD
+0.450+0.26%
交易中 （美东）报价延迟15分钟
425.78B总市值
18.79市盈率 TTM
关于 强生 公司
强生公司（Johnson & Johnson）通过旗下子公司，专注医疗健康领域产品的研发、生产与全球行销。公司聚焦提升人类健康与福祉，并分为 「Innovative Medicine（创新医药）」与「J&J MedTech（医疗科技）」 两大业务 。 Innovative Medicine 深耕免疫学、传染病、神经科学、肿瘤学、肺动脉高压、心血管和代谢疾病等治疗领域。医疗科技部门提供骨科、外科、介入治疗、心血管介入与视觉保健等产品，并因收购 Shockwave Medical 将其商用血管内碎石术 (IVL) 平台纳入，用于 CAD 与 PAD 的微创治疗 ；同时研发数据驱动的外科机器人与数位手术解决方案。
公司简介
公司代码JNJ
公司名称Johnson & Johnson
上市日期Sep 25, 1944
CEOMr. Joaquin Boix Duato
员工数量138100
证券类型Ordinary Share
年结日Sep 25
公司地址One Johnson & Johnson Plaza
城市NEW BRUNSWICK
上市交易所NYSE Consolidated
国家United States of America
邮编08933
电话17325242455
网址https://www.jnj.com/
公司代码JNJ
上市日期Sep 25, 1944
CEOMr. Joaquin Boix Duato
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
--
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
--
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
--
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+20.79%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
12.85K
+17.90%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
10.66K
-64.23%
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
Ms. Marillyn A. Hewson
Ms. Marillyn A. Hewson
Lead Independent Director
Lead Independent Director
3.00K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
--
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
--
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
--
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+20.79%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Oncology-DARZALEX
3.24B
14.79%
Interventional Solutions
2.10B
9.61%
Immunology-STELARA
1.63B
7.42%
Surgery-General
1.32B
6.04%
Surgery-Advanced
1.07B
4.90%
其他
12.53B
57.24%
地区USD
名称
营收
占比
United States
12.30B
56.21%
Europe
5.11B
23.34%
Asia-Pacific, Africa
3.31B
15.12%
Western Hemisphere, excluding U.S.
1.17B
5.33%
业务
地区
业务USD
名称
营收
占比
Oncology-DARZALEX
3.24B
14.79%
Interventional Solutions
2.10B
9.61%
Immunology-STELARA
1.63B
7.42%
Surgery-General
1.32B
6.04%
Surgery-Advanced
1.07B
4.90%
其他
12.53B
57.24%
股东统计
更新时间: 5月13日 周二
更新时间: 5月13日 周二
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.80%
State Street Global Advisors (US)
5.51%
BlackRock Institutional Trust Company, N.A.
5.39%
Geode Capital Management, L.L.C.
2.52%
JP Morgan Asset Management
1.52%
其他
75.26%
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.80%
State Street Global Advisors (US)
5.51%
BlackRock Institutional Trust Company, N.A.
5.39%
Geode Capital Management, L.L.C.
2.52%
JP Morgan Asset Management
1.52%
其他
75.26%
股东类型
持股股东
占比
Investment Advisor
39.00%
Investment Advisor/Hedge Fund
24.11%
Research Firm
3.02%
Pension Fund
2.35%
Bank and Trust
2.18%
Insurance Company
1.62%
Sovereign Wealth Fund
1.42%
Hedge Fund
0.69%
Family Office
0.09%
其他
25.52%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
5920
1.78B
73.89%
-7.65M
2025Q1
6002
1.80B
74.62%
+4.60M
2024Q4
5953
1.78B
74.14%
+8.28M
2024Q3
5699
1.77B
73.47%
+2.69M
2024Q2
5691
1.75B
72.75%
+9.12M
2024Q1
5685
1.73B
71.58%
-6.08M
2023Q4
5686
1.72B
71.40%
-7.80M
2023Q3
5524
1.72B
71.21%
-159.24M
2023Q2
5528
1.87B
71.81%
+6.27M
2023Q1
5490
1.85B
71.21%
-28.44M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
232.98M
9.68%
+1.17M
+0.50%
Mar 31, 2025
State Street Global Advisors (US)
133.79M
5.56%
-666.37K
-0.50%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
129.14M
5.37%
-857.93K
-0.66%
Mar 31, 2025
Geode Capital Management, L.L.C.
59.38M
2.47%
+1.72M
+2.98%
Mar 31, 2025
JP Morgan Asset Management
35.25M
1.47%
+11.21M
+46.62%
Mar 31, 2025
State Farm Insurance Companies
34.37M
1.43%
--
--
Mar 31, 2025
Norges Bank Investment Management (NBIM)
30.36M
1.26%
+1.26M
+4.34%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
24.07M
1%
+1.16M
+5.06%
Mar 31, 2025
Wellington Management Company, LLP
22.65M
0.94%
-1.71M
-7.02%
Mar 31, 2025
BlackRock Asset Management Ireland Limited
19.70M
0.82%
-178.45K
-0.90%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月6日 周三
更新时间: 8月6日 周三
机构名称
占比
iShares U.S. Pharmaceuticals ETF
23.85%
FT Vest DJIA Dogs 10 Target Income ETF
9.78%
VanEck Pharmaceutical ETF
8.38%
First Trust NASDAQ Pharmaceuticals ETF
8.12%
Health Care Select Sector SPDR Fund
7.51%
Proshares Ultra Health Care
7.51%
JPMorgan Healthcare Leaders ETF
7.42%
iShares U.S. Healthcare ETF
7.26%
iShares Core High Dividend ETF
6.49%
Fidelity MSCI Health Care Index ETF
6.48%
查看更多
iShares U.S. Pharmaceuticals ETF
占比23.85%
FT Vest DJIA Dogs 10 Target Income ETF
占比9.78%
VanEck Pharmaceutical ETF
占比8.38%
First Trust NASDAQ Pharmaceuticals ETF
占比8.12%
Health Care Select Sector SPDR Fund
占比7.51%
Proshares Ultra Health Care
占比7.51%
JPMorgan Healthcare Leaders ETF
占比7.42%
iShares U.S. Healthcare ETF
占比7.26%
iShares Core High Dividend ETF
占比6.49%
Fidelity MSCI Health Care Index ETF
占比6.48%
分红派息
近5年累计派现
56.79B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Jan 02, 2025
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025
Feb 18, 2025
Mar 04, 2025
Feb 18, 2025
Oct 15, 2024
JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 10, 2024
Nov 26, 2024
Jul 17, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024
Aug 27, 2024
Sep 10, 2024
Aug 27, 2024
Apr 16, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024
May 21, 2024
Jun 04, 2024
May 20, 2024
Jan 02, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024
Feb 20, 2024
Mar 05, 2024
Feb 16, 2024
Oct 19, 2023
JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023
Nov 21, 2023
Dec 05, 2023
Nov 20, 2023
Jul 20, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023
Aug 28, 2023
Sep 07, 2023
Aug 25, 2023
Apr 18, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023
May 23, 2023
Jun 06, 2023
May 22, 2023
Jan 03, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023
Feb 21, 2023
Mar 07, 2023
Feb 17, 2023
Oct 18, 2022
JNJ.NB Final Cash Dividend of gross USD 1.13 paid on Dec 06, 2022 going ex on Nov 21, 2022
Nov 22, 2022
Dec 06, 2022
Nov 21, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
